Dr. Peter Block interviews Dr. Steve Nissen on the results GLAGOV trial assessing the effects of a PCSK9 inhibitor on the regression or progression of coronary atherosclerosis as assessed by intravascular ultrasound.

Keywords: AHA Annual Scientific Sessions, AHA16, Coronary Artery Disease, Developmental Disabilities, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors

< Back to Listings